Experienced BIO / Pharma Executive adds leadership finances, access to strategic capital and public market readiness
Covington, Kentucky, June 2, 2022 / PRNewswire / – Bexion Pharmaceuticals, Inc., a mid-range biopharmaceutical company that develops innovative treatments for cancer and peripheral chemotherapy-induced peripheral neuropathy (CIPN), announced today that Ms. Joyce LaVicont joined the company’s management team as Chief Financial Officer (CFO).
Ms. LaViscount brings more than 30 years of experience in start-ups in Fortune 100 companies with a variety of leadership roles in finance, accounting and operations. Prior to joining Bexion Pharmaceuticals, Joyce was the Chief Financial Officer of Panavance Therapeutics, a clinical-based pharmaceutical company focused on new oncology therapies. Prior to Panavance, Ms. LaVicont held the positions of Chief Financial Officer and Managing Director of Helius Medical Technologies. $ 110 million to fund corporate development and security listings on both the Nasdaq and the Toronto exchanges. Its foundation in the industry is based on more than 20 years of increased responsibility at Pfizer / Pharmacia, Bristol-Myers Squibb and Endo Pharmaceuticals.
Scott ShivleyCEO and President of Bexion, commented: “Joyce has proven experience in results-oriented leadership, strategic thinking and financial capacity, as well as proven experience in both private and public companies. We look forward to joining our team. and contributes to the further development of Bexion as a company as we promote our flagship product BXQ-350 and continue to build our capital structure ”.
“I am excited to join Bexion’s experienced management team at a key stage in the organization’s growth and look forward to leading the evolution of our capital structure and financial operating environment for the further development of our promising pipeline, ”he said. Joyce LaVicont. “Bexion has stood out for me as a truly scientific organization focused on providing transformational therapies to patients, including our leading candidate BXQ-350, which if approved could change the lives of patients living with colorectal cancer and other solid tumors.”
About Bexion Pharmaceuticals
Bexion Pharmaceuticals, a mid-level clinical biopharmaceutical company, is developing a new generation of biological immunotherapy for the treatment of solid tumors and peripheral chemotherapy-induced peripheral neuropathy (CIPN) with the potential to expand the portfolio of other cancers and more widely. The main candidate for the drug from Bexion is BXQ-350, a first-class biologic containing a multifunctional lysosome activator protein, saposin C and phosphatidylserine.
BXQ-350, “S1P Activator,” has demonstrated preclinical antitumor effects in vitro and in vivo, especially in colorectal, head, and other solid tumors. Bexion has completed two phase 1 programs with one agent for adults and one for children. Phase 1 programs demonstrated a strong safety profile with evidence of single agent activity in a number of tumors including glioblastoma multiforme (GBM), colorectal cancer, and appendix cancer. In addition, other clinical and preclinical data suggest BXQ-350 activity in chemotherapeutic peripheral neuropathy.
Media contact: Margaret van Giles ● 859.757.1652 ● mvangilse@bexionpharma.com.
Statements about the future
THE INFORMATION CONTAINED IN THIS PRESENTATION IS CONFIDENTIAL INFORMATION. THE CORRESPONDENCE, THE INFORMATION ADJUSTED HERE, CANNOT BE COVERED, QUOTED OR REVEALED TO OTHERS. BY VIEWING THIS INFORMATION, YOU CONNECT THE CONFIDENTIAL CROWD OF THIS INFORMATION AND AGREE TO CONDITION TO REFUSE REFUSE REFUSE THIS CONFIDENTIAL INFORMATION IS MADE AVAILABLE TO EACH RECIPIENT ONLY FOR HIS INFORMATION AND MAY BE CORRECTED.
This document is not an offer to sell or a request to purchase any security. This document should not be construed as a prospectus or offer document, and you should not rely on it or use it to form the final basis for any decision, contract, commitment or action in relation to any proposed transaction or otherwise.
This document is private and confidential. You and your directors, officers, employees, agents and affiliates must keep this document and any oral information provided in connection with this document in the strictest confidence and may not transmit, reproduce, distribute or disclose it to or refer to it. publicly, in whole or in part at any time, except with our prior written consent and in accordance with the research instructions prepared in connection with this transaction. If you are not the intended recipient of this document, delete and destroy all copies immediately.
This document has been prepared by the Company, and the analysis contained therein is based in part on certain assumptions and information obtained from the Company and / or from other sources. Neither the Company nor any of its affiliates, officers, employees or agents shall make any representations or warranties, express or implied, as to the fairness, reasonableness, adequacy, accuracy or completeness of the information, statements or opinions, regardless of their source. contained in this document or any oral information provided in this connection, or any data generated by it, and bearing no liability, obligation or liability (direct or indirect, in contract, tort or otherwise) in respect of any from such information. The information and opinions contained in this document are provided as of the date of the document, are subject to change without notice and do not intend to contain all information that may be required to evaluate the company. The information in this document is in draft form and has not been independently verified. The Company and its respective affiliates, officers, employees and agents expressly disclaim any liability that may be based on this document as well as any errors or omissions in it. Neither the Company nor any of their respective affiliates, officers, employees or agents make any representations or warranties, express or implied, that any transaction has been or may be made under the terms or in the manner set forth herein or in this document. with respect to the achievement or reasonableness of future projections, management objectives, estimates, prospects or revenues, if any.
This document and any materials distributed in connection with this document are not intended or intended for distribution or use by any natural or legal person who is a citizen or resident or is located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation, or requiring registration or licensing in such jurisdiction. This document is not an offer to sell or an invitation to offer to buy any securities USA or any other jurisdiction. This document may not be reproduced, distributed, published or transmitted, directly or indirectly, to any person in any jurisdiction if it would violate the relevant laws of such jurisdiction.
See original content for multimedia downloads:https://www.prnewswire.com/news-releases/bexion-pharmaceuticals-inc-welcomes-new-chief-financial-officer-301560661.html
SOURCE Bexion Pharmaceuticals, Inc.
